Emerging drugs for non-alcoholic fatty liver disease.

  title={Emerging drugs for non-alcoholic fatty liver disease.},
  author={Alessandro Federico and Marco Niosi and Camillo Del Vecchio Blanco and Carmelina Loguercio},
  journal={Expert opinion on emerging drugs},
  volume={13 1},
BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is a condition of emerging relevance that includes different forms of chronic liver damage, from a simple fatty infiltration (steatosis) of hepatocytes to steatohepatitis (NASH) with fibrosis. This last form may evolve to cirrhosis and hepatocellular carcinoma. OBJECTIVE To discuss therapeutic management of NAFLD. Theoretically, only patients with non-alcoholic steatohepatitis (NASH) need to be treated, as only NASH may evolve to cirrhosis… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…